Search

Your search keyword '"Ruel, Nora H."' showing total 37 results
Start Over Author "Ruel, Nora H."
37 results on '"Ruel, Nora H."'

1. Differential gene expression analysis of a phase II randomized clinical trial of patients with endometrial cancer (EC) treated with megestrol acetate ± pterostilbene.

Author

Dellinger, Thanh Hue, primary, Wu, Xiwei, additional, Cho, Hyejin, additional, Yost, Susan Elaine, additional, Ruel, Nora H., additional, Invernizzi, Marta, additional, Senguttuvan, Rosemary Noel, additional, Frankel, Paul Henry, additional, Kebria, Mehdi, additional, Han, Ernest Soyoung, additional, Song, Mihae, additional, De Leon, Maria, additional, Eng, Melissa, additional, Tinsley, Raechelle, additional, Schmolze, Daniel, additional, Chang, Sue, additional, and Arias Stella, Javier, additional

Published
2024
Full Text
View/download PDF

2. Pressurized intraperitoneal aerosolized chemotherapy (PIPAC) experience in patients with recurrent low grade serous ovarian carcinoma (LGSOC): sub-cohort report of phase 1 clinical trial.

Author

Nakamura, Brad, Senguttuvan, Rosemary, Ruel, Nora H., Frankel, Paul H., Yost, Susan E., Cole, Sarah, Sue Chang, Jung, Alexander, Eng, Melissa, Tinsley, Raechelle, Stewart, Daphne, Wang, Edward, Cohen, Joshua, Villella, Jeannine, Whelan, Richard L., Merchea, Amit, DePeralta, Danielle K., Cristea, Mihaela, Wakabayashi, Mark T., and Raoof, Mustafa

Subjects
PROGRESSION-free survival, PATIENT experience, PERITONEAL cancer, PERITONEUM diseases, PERITONEUM, OVARIAN cancer
Abstract

Introduction: Low grade serous ovarian carcinoma (LGSOC) is a rare subtype of ovarian cancer (OC) that is challenging to treat due to its relative chemoresistance. Given that LGSOC patients often recur in the peritoneal cavity, novel intraperitoneal (IP) chemotherapy should be explored. Pressurized intraperitoneal aerosolized chemotherapy (PIPAC) is a method that has demonstrated peritoneal disease control in cancers with peritoneal metastases. Methods: NCT04329494 is a US multicenter phase 1 trial evaluating the safety of PIPAC in recurrent ovarian, uterine, and GI cancers with peritoneal metastases. This analysis describes the outcomes of a sub-cohort of four LGSOC patients treated with IP cisplatin 10.5 mg/m², doxorubicin 2.1 mg/m² PIPAC q4-6 weeks. Primary endpoints included dose-limiting toxicities (DLT) and incidence of adverse events (AE). Secondary endpoints were progression free survival (PFS) and treatment response based on radiographic, intraoperative, and pathological findings. Results: Four patients with LGSOC were enrolled of which three were heavily pretreated. Median prior lines of therapy was 5 (range 2-10). Three patients had extraperitoneal metastases, and two patients had baseline partial small bowel obstructive (SBO) symptoms. Median age of patients was 58 (38-68). PIPAC completion rate (=2 PIPACs) was 75%. No DLTs or Clavien-Dindo surgical complications occurred. No G4/G5 AEs were observed, and one G3 abdominal pain was reported. One patient had a partial response after 3 cycles of PIPAC and completed an additional 3 cycles with compassionate use amendment. Two patients came off study after 2 cycles due to extraperitoneal progressive disease. One patient came off study after 1 cycle due to toxicity. Median decrease in peritoneal carcinomatosis index between cycles 1 and 2 was 5.0%. Ascites decreased in 2 out of 3 patients who had =2 PIPACs. Median PFS was 4.3 months (1.7-21.6), median overall survival was 11.6 months (5.4-30.1), and objective response rate was 25%. Conclusion: PIPAC with cisplatin/doxorubicin is well tolerated in LGSOC patients without baseline SBO symptoms. IP response was seen in 2 out of 3 patients that completed =2 PIPAC cycles. Further study of PIPAC for patients with recurrent disease limited to the IP cavity and with no partial SBO symptoms should be considered. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

4. Indiana Pouch Continent Cutaneous Urinary Diversion After Robotic-assisted Radical Cystectomy: A 16-Year Experience.

Author

Kim, Albert H., Ruel, Nora H., Yamzon, Jonathan, Zhumkhawala, Ali-Ashgar, Lau, Clayton S., Yuh, Bertram E., and Chan, Kevin G.

Subjects
*URINARY diversion, *CYSTECTOMY, *CONTINENTS, *CANCER prognosis, *LENGTH of stay in hospitals, *PATIENT preferences
Abstract

Population-based practice patterns in the United States reveal continent diversions are only performed in 8%-10.4% of patients. 1-4 Ideally, for patients undergoing radical cystectomy the choice of urinary diversion should be influenced by clinical factors and patient preference, with discussions surrounding quality of life. Unfortunately, receipt of continent diversion has been shown to be influenced by a plethora of other factors such as surgeon preference/training, geography, socioeconomic status, gender, and hospital volume. 1-3 Thus, by providing detailed instruction and long-term follow-up, we hope to mitigate some of these disparities by changing the perceptions regarding feasibility and complications of continent diversions. To provide step-by-step instruction and to report long-term clinical outcomes in bladder cancer patients receiving an Indiana pouch continent cutaneous urinary diversion (CCUD) after robot-assisted radical cystectomy. After Institutional Review Board approval, a prospectively maintained bladder cancer database was queried for patients with T1-T4, N0-N1, M0 bladder cancer undergoing radical cystectomy with CCUD at a tertiary referral center from 2004 to 2020. Complications at 30- and 90-day were recorded according to the Clavien-Dindo classification. Continence rates were recorded by chart review. A total of 97 patients were included with a median follow-up of 93 months. Clinically, 91.8% had ≤T2 disease and 29.9% received neoadjuvant chemotherapy. The median length of surgery was 8.0 hours, length of hospital stay was 8.3 days, and urinary continence rate was 99.0%. The overall complication rate was 73.2% and 76.5% at 30- and 90-day, respectively. The major complication rate (Clavien III-V) was 17.5% at 30-day and 22.7% at 90-day. The most common major complications were abdominal infection and uretero-colonic stricture. The readmission rate was 21.4% and median overall survival was 108 months. CCUD provides exceptional functional outcomes with acceptable complication rates compared to other diversion types. CCUD is a reliable reconstructive option and with this step-by-step video as a reference, we hope it will be offered to more patients. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

7. Cisplatin-induced nephrotoxicity in hyperthermic intraperitoneal chemotherapy (HIPEC) is mitigated by sodium thiosulfate: Clinical and toxicotranscriptomic results of a prospective trial.

Author

Lugo Santiago, Nicole, primary, Han, Ernest Soyoung, additional, Raoof, Mustafa, additional, Wu, Xiwei, additional, Cho, Hyejin, additional, Lee, Stephen, additional, Lin, Wei-Chien, additional, Lin, Jeff Feng-Hsu, additional, Stewart, Daphne B., additional, Ruel, Nora H., additional, Wang, Edward Wenge, additional, Paz, Isaac Benjamin, additional, Wakabayashi, Mark Tsuneo, additional, Rodriguez-Rodriguez, Lorna, additional, Cristea, Mihaela C., additional, and Dellinger, Thanh Hue, additional

Published
2022
Full Text
View/download PDF

12. Influence of Germline BRCA Genotype on the Survival of Patients with Triple-Negative Breast Cancer

Author

Villarreal-Garza, Cynthia, primary, Ferrigno, Ana S., additional, Aranda-Gutierrez, Alejandro, additional, Frankel, Paul H., additional, Ruel, Nora H., additional, Fonseca, Alan, additional, Narod, Steven, additional, Chavarri-Guerra, Yanin, additional, Sifuentes, Erika, additional, Magallanes-Hoyos, Maria Cristina, additional, Herzog, Josef, additional, Castillo, Danielle, additional, Alvarez-Gomez, Rosa M., additional, Mohar-Betancourt, Alejandro, additional, and Weitzel, Jeffrey N., additional

Published
2021
Full Text
View/download PDF

16. A phase I study of mirvetuximab soravtansine (MIRV) and gemcitabine (G) in patients (Pts) with selected frα-positive solid tumors: Results in the ovarian cancer (EC) cohort.

Author

Cristea, Mihaela C., primary, Ruel, Nora H., additional, Frankel, Paul Henry, additional, Synold, Timothy W., additional, Stewart, Daphne B., additional, Wang, Edward Wenge, additional, Jung, Alex, additional, Wilczynski, Sharon, additional, Tran, Michael, additional, Konecny, Gottfried E., additional, Eng, Melissa, additional, Kilpatrick, Lindsay, additional, Chen, Yi-Jen, additional, Glaser, Scott, additional, Dellinger, Thanh Hue, additional, Hakim, Amy, additional, Lee, Stephen, additional, Morgan, Robert, additional, and Han, Ernest Soyoung, additional

Published
2021
Full Text
View/download PDF

21. Spirituality in cancer patients on phase 1 clinical trials

Author

Ferrell, Betty, primary, Chung, Vincent, additional, Koczywas, Marianna, additional, Borneman, Tami, additional, Irish, Terry L., additional, Ruel, Nora H., additional, Azad, Nilofer S., additional, Cooper, Rhonda S., additional, and Smith, Thomas J., additional

Published
2020
Full Text
View/download PDF

23. Real-time indocyanine green angiography with the SPY fluorescence imaging platform decreases benign ureteroenteric strictures in urinary diversions performed during radical cystectomy

Author

Shen, Jim K., primary, Jamnagerwalla, Juzar, additional, Yuh, Bertram E., additional, Bassett, Mitchell R., additional, Chenam, Avinash, additional, Warner, Jonathan N., additional, Zhumkhawala, Ali, additional, Yamzon, Jonathan L., additional, Whelan, Christopher, additional, Ruel, Nora H., additional, Lau, Clayton S., additional, and Chan, Kevin G., additional

Published
2019
Full Text
View/download PDF

33. Identification of a 4-microRNA Signature for Clear Cell Renal Cell Carcinoma Metastasis and Prognosis

Author

Wu, Xiwei, primary, Weng, Lihong, additional, Li, Xuejun, additional, Guo, Chao, additional, Pal, Sumanta K., additional, Jin, Jennifer M., additional, Li, Yuping, additional, Nelson, Rebecca A., additional, Mu, Bing, additional, Onami, Susan H., additional, Wu, Jeffrey J., additional, Ruel, Nora H., additional, Wilczynski, Sharon P., additional, Gao, Hanlin, additional, Covarrubias, Maricela, additional, Figlin, Robert A., additional, Weiss, Lawrence M., additional, and Wu, Huiqing, additional

Published
2012
Full Text
View/download PDF

35. Radioiodinated versus Radiometal-Labeled Anti–Carcinoembryonic Antigen Single-Chain Fv-Fc Antibody Fragments: Optimal Pharmacokinetics for Therapy

Author

Kenanova, Vania, primary, Olafsen, Tove, additional, Williams, Lawrence E., additional, Ruel, Nora H., additional, Longmate, Jeffrey, additional, Yazaki, Paul J., additional, Shively, John E., additional, Colcher, David, additional, Raubitschek, Andrew A., additional, and Wu, Anna M., additional

Published
2007
Full Text
View/download PDF

37. Controlling the dorsal venous complex during robotic prostatectomy.

Author

Talug C, Josephson DY, Ruel NH, Lau C, Kawachi MH, and Wilson TG

Subjects
Adult, Aged, Aged, 80 and over, Humans, Logistic Models, Male, Middle Aged, Multivariate Analysis, Neoplasm Grading, Neoplasm Recurrence, Local epidemiology, Prostatic Neoplasms pathology, Surgical Stapling, Suture Techniques, Prostatectomy methods, Prostatic Neoplasms surgery, Robotics
Abstract

Introduction: The objective of our study was to determine whether dorsal venous complex (DVC) control technique influences positive apical margins following robotic assisted laparoscopic radical prostatectomy (RALRP)., Materials and Methods: One thousand fifty-eight patients who underwent RALRP at City of Hope from June 2007 to October 2009 were assessed. Endoscopic stapling and suture ligature of the DVC were compared. Positive apical margins were identified and compared based on DVC-control technique. Recurrence probability was estimated using the Kaplan-Meier method, and logistic regression analysis was used to predict the odds of positive apical margins., Results: Of 1058 patients, 633 (60%) underwent endoscopic stapling, and 425 (40%) had suture ligature. The groups had similar baseline characteristics including age and body mass index. We observed a statistically different PSA (5.4 ng/mL versus 5.2 ng/mL, p = 0.03) and operative time (2.8 hours versus 2.7 hours, p = 0.02) between stapling and suture groups, but the actual difference was small. Operative time, Gleason score, pathologic stage, and overall positive margin rates were not significantly different between groups. Positive apical margins were observed in 39 (6%) and 27 (6%) patients in the staple and suture groups, respectively. Multivariate analysis showed that the positive apical margin rate was greater in patients with higher pathologic stage and final pathological Gleason score., Conclusions: During RALRP, there is no difference in positive apical margin rate when the DVC is controlled using either endoscopic stapling or suture ligature. However, patients with a higher pathologic stage and final pathologic Gleason score are at higher risk for positive apical surgical margins.

Published
2012

Catalog

Books, media, physical & digital resources
See catalog results